Cosmos Health Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited. Cosmos Health is an international healthcare group focused on pharmaceutical and healthcare distribution and proprietary nutraceuticals, including Sky Premium Life and Mediterranation. It operates primarily in Greece, with operations in the UK and expansion plans across other markets.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 or comparison |
|---|---|---|
| Revenue | $12.35 million | $13.07 million; down 5.5% |
| Gross profit / margin | $0.96 million / 7.8% | $1.89 million / 14.5% |
| Operating expenses | $3.61 million | $1.65 million |
| Operating income (loss) | $(2.65) million | $0.24 million |
| Net income (loss) | $(0.46) million | $0.20 million |
| Operating cash flow | $(6.34) million | $(2.34) million |
| Cash and cash equivalents | $12.04 million at March 31, 2023 | $20.75 million at December 31, 2022 |
| Working capital | $32.08 million at March 31, 2023 | $34.30 million at December 31, 2022 |
Investing activities used $4.49 million, principally for a $4.55 million loan to related party Cana Laboratories Holding. Financing activities provided $2.24 million, including $4.75 million from common stock issuance, partly offset by debt and credit-line repayments. At quarter-end, lines of credit were $4.71 million and notes payable were $3.51 million; these figures exclude lease liabilities. Current liabilities were $18.55 million. The company reported compliance with line-of-credit covenants.
Material changes and unusual items
- Revenue fell modestly, but gross profit declined 49%, which management attributed to discounted and reduced sales of high-margin nutraceuticals as the company sought to lower overdue receivables.
- Operating expenses more than doubled, with higher general and administrative, compensation, and advertising costs.
- Other income included $1.91 million of debt-extinguishment gains, including a $1.55 million write-off of a share-settled debt obligation following termination of the Marathon agreement and $0.31 million of trade-debt forgiveness. These gains partly offset the operating loss.
- Q1 2022 included a $5.79 million deemed dividend related to warrants, making that period’s $5.59 million loss attributable to common stockholders substantially larger than its $0.20 million net income. Q1 2023 loss attributable to common stockholders was $0.46 million.
- Cash declined by $8.71 million during the quarter. Related-party advances and prepayments are material: the company made the Cana loan and reported significant related-party receivables and prepaid balances, including amounts involving Doc Pharma.
Outlook, risks, and contingencies
- No numerical revenue or earnings guidance was provided. Management described its outlook as positive and plans to expand distribution, product offerings, e-commerce, and geographic reach. It aims to grow its proprietary nutraceutical portfolio to 150 SKUs by year-end 2023.
- Management expects to use available cash and may rely on debt or equity financing, investing proceeds, or management loans; management is not obligated to provide funding. The filing warns that failure to meet requirements could jeopardize Nasdaq quotation and SEC reporting status.
- Subsequent events: ZipDoctor acquisition for $150,000 cash closed April 3, 2023. On May 3, the company acquired its CosmoFarm operating building for approximately $1.07 million. A May 8 agreement to acquire Cana Holdings for approximately $1.67 million in cash and restricted shares remained subject to closing conditions.
- Risks include pharmaceutical pricing and regulation, competition, supply-chain disruption, foreign-exchange movements, and economic conditions. The filing notes uncertainty concerning SkyPharm’s wholesale-license renewal following rejection by the Greek medicines agency; the agency had not updated the company on the implications.
- The company reported pending legal matters, including a tax-related appeal seeking recovery of approximately $99,644 already paid; management stated the listed matters were not expected to have a material financial or operational impact.
- Management concluded disclosure controls were partially effective, citing previously identified material weaknesses involving segregation of duties and internal-control structure review. Remediation efforts were ongoing.
Important facts for investors to verify
- Whether cash burn and collection of overdue customer receivables improve, particularly given the $6.34 million operating cash outflow and the revenue deferrals/discounts involving distributor Medihelm.
- The recoverability, terms, and related-party governance of the $4.46 million Cana loan and other related-party receivables and prepayments.
- Whether the Cana acquisition closes, how it is funded, and the effect of the existing secured loan to Cana; also assess the integration and performance of the completed ZipDoctor acquisition.
- The status and business impact of SkyPharm’s wholesale-license issue, and developments in the tax appeal and other legal matters.
- Potential dilution: 4.19 million warrants were outstanding and exercisable at March 31, 2023, compared with approximately 10.62 million common shares issued at quarter-end.
- Progress in remediating control weaknesses and maintaining access to financing and Nasdaq listing compliance.